Research presented at ENDO 2026 reported that postmenopausal women taking menopausal hormone therapy faced a substantially lower risk of developing low bone mineral density compared with women not using hormone therapy. The finding was described and interpreted by Diego Espinoza-Peralta, M.D., M.Sc., who served as principal investigator for the retrospective cohort analysis.
The news summary frames this result as a potential factor that could influence clinical decision-making about hormone therapy use in selected patients, especially given longstanding safety concerns that have led many women to avoid these treatments.
The retrospective cohort included 387 postmenopausal women who had dual-energy X-ray absorptiometry (DXA) scans performed between 2021 and 2025. Within that cohort, 33% were identified as users of menopausal hormone therapy and 67% as non-users.
The outcome of interest was low bone mineral density, which the study defined as either osteopenia or osteoporosis as measured on DXA at spine and hip sites.
No further methodological specifics—such as the hormone preparations, doses, route of administration, duration of therapy, or the exact DXA criteria used for osteopenia versus osteoporosis—were reported in the source article.
The analysis found that women taking menopausal hormone therapy had approximately a 69% lower risk of presenting with low bone mineral density in the spine and hip compared with those not taking hormone therapy. This reduction in risk was the primary result emphasized in the report and in the video presentation summarized by the source.
The summary highlights that this protective association persisted after statistical adjustment for several patient factors, lending support to the interpretation that the effect may be independent of those covariates.
According to the report, the observed association remained after the researchers accounted for a set of potential confounders, including age, time since menopause, vitamin D levels, smoking status, and other health conditions. Based on these adjusted analyses, the investigator stated that menopausal hormone therapy appears to independently protect bone, rather than the association being attributable to measured confounding.
The source does not provide the detailed statistical outputs (for example, adjusted relative risks or confidence intervals) or the modeling approach used; those elements were not reported in the news summary.
Diego Espinoza-Peralta, M.D., M.Sc., framed the findings as a reason to revisit how clinicians and patients weigh the risks and benefits of menopausal hormone therapy. He noted that many women have historically avoided hormone therapy because of safety concerns and warning labels, and suggested that the new data “shifts the conversation from ‘avoid if possible’ to ‘reconsider in the right patient.’”
The report suggests two potential clinical implications: that menopausal hormone therapy may offer an added benefit in preserving bone mineral density and that clinicians might consider this protective effect when counseling women, particularly those early after menopause who are seeking relief from vasomotor or other menopausal symptoms.
The news piece also links bone preservation with possible downstream reductions in fracture risk, disability, and loss of independence, but the study as reported focused on DXA-defined low bone mineral density rather than direct fracture endpoints.
The source-provided summary did not include several important details that clinicians may seek before changing practice, including:
These items were not reported in the source article and therefore cannot be inferred here.
A retrospective cohort presented at ENDO 2026 and summarized by the source indicates that postmenopausal women using menopausal hormone therapy had about a 69% lower risk of DXA-defined low bone mineral density in the spine and hip compared with non-users. The association persisted after adjustment for several covariates, and the investigators interpreted the finding as evidence that hormone therapy may independently protect bone. The short news summary emphasizes possible implications for clinical counseling, particularly for women early after menopause, but does not provide detailed methodology, statistical results, or safety data. Those details would be needed to fully assess clinical applicability and to weigh benefits against potential risks for individual patients.